Additive prognostic value of carbohydrate antigen-125 over frailty in patients undergoing transcatheter aortic valve replacement.
aortic valve stenosis
biomarkers
carbohydrate antigen-125
frailty
transcatheter aortic valve replacement
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
14
04
2020
accepted:
26
05
2020
pubmed:
1
7
2020
medline:
25
9
2021
entrez:
30
6
2020
Statut:
ppublish
Résumé
To evaluate the additive prognostic value of myocardial, inflammatory, and renal biomarkers according to frailty status in patients undergoing transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS). A total of 111 subjects who underwent TAVR at Hospital Italiano de Buenos Aires, Argentina between January 2016 and December 2018 were retrospectively reviewed. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity troponin T (hs-cTnT), C-reactive protein (CRP), cystatin-c (Cys-C) and carbohydrate antigen-125 (CA-125) were assessed prior to TAVR. Frailty status was assessed according to the fried physical frailty phenotype (FPFP). The primary endpoint was defined as all-cause death and/or readmission for worsening congestive heart failure (CHF) within the first year after TAVR. Of the 111 patients included, 48/111 (43%) were considered to be "frail" according to the FPFP. Among biomarkers, we found CA-125 to be strongly associated with the primary endpoint (p = .006). CA-125 ≥ 18.2 U/ml was present in 41% and was associated with a higher rate of the primary endpoint (31% vs. 9%; p = .003). After multivariable adjustment, CA-125 ≥ 18.2 U/ml (hazard ratio [HR] 3.17; p = .024) was the only independent predictor of the primary endpoint. Finally, the inclusion of CA-125 to frailty significantly improved C-index (0.68-0.74; p < .05), and provided a Net Reclassification Improvement (NRI) of 0.34 (95% CI 0.19-0.49, p = .031), largely through reductions in risk estimates among pre-frail and frail patients. CA-125, a tumor biomarker, outperformed frailty for predicting the primary endpoint within the first year after TAVR.
Sections du résumé
BACKGROUND
To evaluate the additive prognostic value of myocardial, inflammatory, and renal biomarkers according to frailty status in patients undergoing transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS).
METHODS
A total of 111 subjects who underwent TAVR at Hospital Italiano de Buenos Aires, Argentina between January 2016 and December 2018 were retrospectively reviewed. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity troponin T (hs-cTnT), C-reactive protein (CRP), cystatin-c (Cys-C) and carbohydrate antigen-125 (CA-125) were assessed prior to TAVR. Frailty status was assessed according to the fried physical frailty phenotype (FPFP). The primary endpoint was defined as all-cause death and/or readmission for worsening congestive heart failure (CHF) within the first year after TAVR.
RESULTS
Of the 111 patients included, 48/111 (43%) were considered to be "frail" according to the FPFP. Among biomarkers, we found CA-125 to be strongly associated with the primary endpoint (p = .006). CA-125 ≥ 18.2 U/ml was present in 41% and was associated with a higher rate of the primary endpoint (31% vs. 9%; p = .003). After multivariable adjustment, CA-125 ≥ 18.2 U/ml (hazard ratio [HR] 3.17; p = .024) was the only independent predictor of the primary endpoint. Finally, the inclusion of CA-125 to frailty significantly improved C-index (0.68-0.74; p < .05), and provided a Net Reclassification Improvement (NRI) of 0.34 (95% CI 0.19-0.49, p = .031), largely through reductions in risk estimates among pre-frail and frail patients.
CONCLUSIONS
CA-125, a tumor biomarker, outperformed frailty for predicting the primary endpoint within the first year after TAVR.
Substances chimiques
Carbohydrates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E263-E273Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.
Leon MB, Smith CR, Mack M, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Mack M, Leon MB, Thourani V, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):2438-2488.
Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL, Mack MJ. Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2008;135:180-187.
Oury C, Nchimi A, Lancellotti P, Bergler-Klein J. Can blood biomarkers help predicting outcome in transcatheter aortic valve implantation? Front Cardiovasc Med. 2018;5:31.
Redfors B, Furer A, Lindman BR, et al. Biomarkers in aortic stenosis: a systematic review. Struct Heart. 2017;1(1-2):18-30.
Husser O, Nunez J, Burgdorf C, et al. Improvement in risk stratification in transcatheter aortic valve implantation using a combination of the tumor marker CA-125 and the logistic EuroSCORE. Rev Esp Cardiol. 2017;70(3):186-193.
Bouillon K, Kivimaki M, Hamer M, et al. Measures of frailty in population-based studies: an overview. BMC Geriatr. 2013;13(1):64.
Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53-61.
Chauhan D, Haik N, Merlo A, et al. Quantitative increase in frailty is associated with diminished survival after transcatheter aortic valve replacement. Am Heart J. 2016;182:146-154.
Yao S, Guo J, Shi G, et al. Association of BNP with frailty in elderly population: Rugao longevity and ageing study. J Nutr Health Aging. 2019;23(1):73-78.
Samson L, Boots A, Verschuren W, et al. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Exp Gerontol. 2019;125:110674.
Hart A, Blackwell TL, Paudel ML, et al. Cystatin C and the risk of frailty and mortality in older man. J Gerontol A Biol Sci Med Sci. 2017;72(7):965-970.
Ohara M, Kohara K, Tabara Y, et al. Sarcopenic obesity and arterial stiffness, pressure wave reflection and central pulse pressure: the J-SHIPP study. Int J Cardiol. 2014;174:214-217.
Walker K, Walston J, Gottesman R, et al. Midlife systemic inflammation is associated with frailty in later life: the ARIC study. J Gerontol A Biol Sci Med Sci. 2019;74(3):343-349.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
Bahat G, Yilmaz O, Kiliç C, Oren MM, Karan MA. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging. 2018;22(8):898-903.
Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372-392.
Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. N Engl J Med. 2005;352(1):20-28.
Arangalage D, Cimadevilla C, Alkhoder S, et al. Agreement between the new EuroSCORE II, the logistic EuroSCORE and the Society of Thoracic Surgeons score: implications for transcatheter aortic valve implantation. Arch Cardiovasc Dis. 2014;107(6-7):353-360.
Lindman BR, Alexander KP, O'Gara PT, et al. Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014;7(7):707-716.
Romeo FJ, Seropian IM, Arora S, et al. Prognostic impact of myocardial contraction fraction in patients undergoing transcatheter aortic valve replacement for aortic stenosis. Cardiovasc Diagn Ther. 2020;10(1):12-23.
Lindman BR, Clavel MA, Abu-Alhayja'a R, et al. Multimarker approach to identify patients with higher mortality and rehospitalization rate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv. 2018;11(21):2172-2181.
Nuñez J, Bayés-Genís A, Revuelta-López E, et al. Clinical role of CA-125 in worsening heart failure. JACC Heart Fail. 2020;8(5):386-397.
Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig. 1981;68(5):1331-1337.
Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355-366.
Hung CL, Hung TC, Lai YH, Lu CS, Wu YJ, Yeh HI. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. Biomark Res. 2013;1(1):25.
Yalta K, Yilmaz A, Turgut OO, et al. Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. Adv Ther. 2006;23(6):1052-1059.
Antonini-Canterin F, Popescu BA, Popescu AC, et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol. 2008;128(3):406-412.
Varol E, Yücel H, Arslan A, et al. Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars. 2012;40(4):309-315.
Rheude T, Pellegrini C, Reinhard W, et al. Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation. Biomarkers. 2018;23(3):299-304.
Husser O, Nunez J, Nunez E, et al. Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2013;6(5):487-496.
Durand E, Doutriaux M, Bettinger N, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(23):2426-2436.
Rheude T, Pellegrini C, Núñez J, et al. Differential prognostic value of galectin-3 according to carbohydrate antigen 125 levels in transcatheter aortic valve implantation. Rev Esp Cardiol. 2019;72(11):907-915.
Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197-203.
de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11(9):811-817.
Ayhan H, Kasapkara HA, Durmaz T, et al. Evaluation of CA-125 and NT-proBNP values in patients undergoing transcatheter aortic valve implantation. J Geriatr Cardiol. 2015;12(2):100-106.
Rheude T, Pellegrini C, Schmid H, et al. Comparison of carbohydrate antigen 125 and N-terminal pro-brain natriuretic peptide for risk prediction after transcatheter aortic valve implantation. Am J Cardiol. 2018;121(4):461-468.